Exact Sciences Cor (EXAS) Stock Price, Quote & News

Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic,...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 608 284 5700

Website: www.exactsciences.com

Address:

5505 Endeavor Lane, Madison, United States

highnihilism Sep. 16 at 2:47 PM

Biotech → $SMMT Summit Therapeutics $EXAS Exact Sciences $BEAM Beam Therapeutics $TGTX TG Therapeutics $RXRX Recursion Pharmaceuticals

0 · Reply

nUme22 Sep. 16 at 2:20 PM

$EXAS this should have pumped this a bit more.. "Exact Sciences unveils Cancerguard™, a groundbreaking multi-cancer early detection (MCED) blood test."

0 · Reply

BillionerOfKing Sep. 16 at 1:55 PM

$EXAS Current Stock Price: $52.87 Contracts to trade: $55 EXAS Sep 19 2025 Call Entry: $0.58 Exit: $0.74 ROI: 29% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Rach8672 Sep. 16 at 12:16 PM

$EXAS why the drop on no news

1 · Reply

prodigy81 Sep. 15 at 7:16 PM

$EXAS Hmm....it seems this company has similar product as $GRAL. Anyone has good report to compare CancerGuard and GRAL's Galleri®?

1 · Reply

SweepAlex Sep. 15 at 9:12 AM

$EXAS Sensitive to interest rates and consumer spending; watch guidance

1 · Reply

MoneyGroupLLC Sep. 13 at 10:23 AM

Enter: $EXAS OCT 03 2025 $56 CALLS Buy in Price: $2.50 - $2.85 Take Profit: $2.80 Stop Bleeding: $2.20 ROI Potential: 12% Exit Within: 37 Minutes https://moneygroup.us/alerts

0 · Reply

kd77799 Sep. 12 at 7:26 PM

$EXAS Just got in. Expecting to reach atleast $90 within next 2 quarters.

1 · Reply

ZacksResearch Sep. 12 at 2:18 PM

$EXAS launches Cancerguard — a game-changer in cancer detection? 🩺💉 This multi-cancer early detection blood test aims to catch over 50 cancer types early. Over the next decade, using Exact Sciences’ MCED technology with current methods could potentially reduce stage IV diagnoses by 42%. EXAS shares jumped 2.2% on the news, with a 29.8% rally in the past 6 months 🔥. Discover the full potential here 👉 https://www.zacks.com/stock/news/2750591/exact-sciences-launches-cancerguard-mced-blood-test-stock-climbs?cid=sm-stocktwits-2-2750591-body-12206&ADID=SYND_STOCKTWITS_TWEET_2_2750591_BODY_12206

0 · Reply

ZacksResearch Sep. 12 at 1:11 PM

$EXAS just dropped a game-changer 🚀 The company launched its Cancerguard multi-cancer early detection blood test — and the stock is already climbing on the news. Full story here 👉 https://www.zacks.com/stock/news/2750591/exact-sciences-launches-cancerguard-mced-blood-test-stock-climbs?cid=sm-stocktwits-2-2750591-teaser-12165&ADID=SYND_STOCKTWITS_TWEET_2_2750591_TEASER_12165

0 · Reply

Exact Sciences CEO on Launch of Multi-Cancer Blood Test

Sep 10, 2025, 6:30 AM EDT - 6 days ago

Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

Sep 9, 2025, 4:49 PM EDT - 7 days ago

Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Sep 3, 2025, 4:14 PM EDT - 13 days ago

Exact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 22, 2025, 8:05 AM EDT - 25 days ago

Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®

Aug 19, 2025, 6:00 AM EDT - 4 weeks ago

Exact Sciences to Participate in September Investor Conferences

Aug 11, 2025, 8:01 AM EDT - 5 weeks ago

Top 3 Health Care Stocks That Are Preparing To Pump This Month

OM TNDM

Aug 7, 2025, 9:45 PM EDT - 5 weeks ago

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

ACLX BSX EW GH ISRG LLY MASI

Aug 7, 2025, 2:56 PM EDT - 5 weeks ago

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Aug 6, 2025, 11:11 PM EDT - 5 weeks ago

Exact Sciences Corporation (EXAS) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 5 weeks ago

Exact Sciences Announces Second Quarter 2025 Results

Aug 6, 2025, 4:05 PM EDT - 5 weeks ago

Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

Jul 31, 2025, 7:00 AM EDT - 6 weeks ago

Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test

Jul 14, 2025, 6:00 AM EDT - 2 months ago

Exact Sciences Schedules Second Quarter 2025 Earnings Call

Jul 10, 2025, 11:19 AM EDT - 2 months ago

Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences' '781 Patent

Jul 9, 2025, 6:00 AM EDT - 2 months ago

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

May 28, 2025, 6:05 AM EDT - 3 months ago

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

May 27, 2025, 4:05 PM EDT - 4 months ago

Exact Sciences to Participate in June Investor Conference

May 22, 2025, 5:05 PM EDT - 4 months ago

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

May 12, 2025, 10:00 AM EDT - 4 months ago

Exact Sciences Earns 2025 Great Place To Work® Certification™

May 2, 2025, 12:52 PM EDT - 4 months ago

Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling

May 2, 2025, 9:18 AM EDT - 4 months ago

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

May 2, 2025, 6:00 AM EDT - 4 months ago

Exact Sciences to Participate in May Investor Conference

May 1, 2025, 8:47 PM EDT - 4 months ago

Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 4 months ago

Exact Sciences Announces First-Quarter 2025 Results

Apr 29, 2025, 6:59 AM EDT - 5 months ago

Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025

Apr 22, 2025, 6:00 AM EDT - 5 months ago

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

Apr 14, 2025, 6:00 AM EDT - 5 months ago

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Apr 1, 2025, 6:00 AM EDT - 6 months ago

Exact Sciences Schedules First Quarter 2025 Earnings Call

Mar 31, 2025, 6:00 AM EDT - 6 months ago

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

Mar 12, 2025, 9:00 AM EDT - 6 months ago

Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

Mar 12, 2025, 5:00 AM EDT - 6 months ago

New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency

Feb 24, 2025, 6:00 AM EST - 7 months ago

Exact Sciences to Participate in March Investor Conferences

Feb 24, 2025, 12:16 AM EST - 7 months ago

Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point

Feb 19, 2025, 8:37 PM EST - 7 months ago

Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 4:05 PM EST - 7 months ago

Exact Sciences Announces Fourth Quarter 2024 Results

Feb 18, 2025, 7:05 AM EST - 7 months ago

U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact Sciences

Feb 5, 2025, 8:00 AM EST - 7 months ago

Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing

Feb 3, 2025, 6:00 AM EST - 8 months ago

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

Jan 21, 2025, 5:05 PM EST - 8 months ago

Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium

Jan 21, 2025, 5:05 PM EST - 8 months ago

New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients

Jan 13, 2025, 1:04 PM EST - 8 months ago

Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market

Jan 12, 2025, 7:00 PM EST - 8 months ago

Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

Jan 2, 2025, 6:00 AM EST - 9 months ago

Exact Sciences to Participate in J.P. Morgan Healthcare Conference

Dec 9, 2024, 10:01 AM EST - 10 months ago

AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates

Dec 4, 2024, 11:06 AM EST - 10 months ago

Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

Dec 3, 2024, 12:02 PM EST - 10 months ago

Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)

Dec 2, 2024, 9:30 AM EST - 10 months ago

Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening

Nov 26, 2024, 1:24 PM EST - 10 months ago

Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)

Nov 26, 2024, 12:21 PM EST - 10 months ago

Why Is Exact Sciences Stock Trading Higher On Monday?

highnihilism Sep. 16 at 2:47 PM

Biotech → $SMMT Summit Therapeutics $EXAS Exact Sciences $BEAM Beam Therapeutics $TGTX TG Therapeutics $RXRX Recursion Pharmaceuticals

0 · Reply

nUme22 Sep. 16 at 2:20 PM

$EXAS this should have pumped this a bit more.. "Exact Sciences unveils Cancerguard™, a groundbreaking multi-cancer early detection (MCED) blood test."

0 · Reply

BillionerOfKing Sep. 16 at 1:55 PM

0 · Reply

Rach8672 Sep. 16 at 12:16 PM

$EXAS why the drop on no news

1 · Reply

prodigy81 Sep. 15 at 7:16 PM

$EXAS Hmm....it seems this company has similar product as $GRAL. Anyone has good report to compare CancerGuard and GRAL's Galleri®?

1 · Reply

SweepAlex Sep. 15 at 9:12 AM

$EXAS Sensitive to interest rates and consumer spending; watch guidance

1 · Reply

MoneyGroupLLC Sep. 13 at 10:23 AM

Enter: $EXAS OCT 03 2025 $56 CALLS Buy in Price: $2.50 - $2.85 Take Profit: $2.80 Stop Bleeding: $2.20 ROI Potential: 12% Exit Within: 37 Minutes https://moneygroup.us/alerts

0 · Reply

kd77799 Sep. 12 at 7:26 PM

$EXAS Just got in. Expecting to reach atleast $90 within next 2 quarters.

1 · Reply

ZacksResearch Sep. 12 at 2:18 PM

0 · Reply

ZacksResearch Sep. 12 at 1:11 PM

0 · Reply

Spikesup Sep. 12 at 4:02 AM

$EXAS Can feel it brewing......

0 · Reply

Rach8672 Sep. 11 at 10:51 PM

$EXAS bought more today

1 · Reply

ManyThanks212 Sep. 11 at 10:02 PM

$EXAS $90 soon

0 · Reply

Woodman7 Sep. 11 at 8:24 PM

$EXAS - yeeaassss!

0 · Reply

Thestocktraderhubzee Sep. 11 at 5:26 PM

$EXAS Craig-Hallum Maintains Buy on Exact Sciences, Raises Price Target to $85

0 · Reply

JarvisFlow Sep. 11 at 5:22 PM

Craig-Hallum has adjusted their stance on Exact Sciences ( $EXAS ), setting the rating to Buy with a target price of 65 → 85.

0 · Reply

Woodman7 Sep. 10 at 11:38 PM

$EXAS - feel like two of my primary holdings, Exact Sciences and Pagaya, $PGY , should have been up significantly today and instead both tumbled . Exas put out a very promising PR this morning about launching its new CANCERGUARD blood test after two consecutive great conference presentations. And, pgy should have popped on the benign inflation data this morning plus the IPO of their partner, $KLAR (Klarna) today. Sometimes the market reactions make no sense….

1 · Reply

ZacksResearch Sep. 10 at 3:06 PM

Can $EXAS overcome the 13.6% drop over the past year? 📉 🔬 Strong growth potential with Cologuard & Oncotype DX tests 📈 Estimated long-term earnings growth rate of 30.1% vs. industry’s 21% ⚠️ Faces tough competition and macroeconomic challenges See if EXAS can navigate these headwinds 👉 https://www.zacks.com/stock/news/2749407/should-you-continue-to-hold-exas-stock-in-your-portfolio?cid=sm-stocktwits-2-2749407-body-11744&ADID=SYND_STOCKTWITS_TWEET_2_2749407_BODY_11744

0 · Reply

ZacksResearch Sep. 10 at 2:06 PM

$EXAS — hold or fold? 🤔 The stock’s long-term potential is in question, and the latest analysis digs into whether keeping it in your portfolio still makes sense. Full breakdown here 👉 https://www.zacks.com/stock/news/2749407/should-you-continue-to-hold-exas-stock-in-your-portfolio?cid=sm-stocktwits-2-2749407-teaser-11699&ADID=SYND_STOCKTWITS_TWEET_2_2749407_TEASER_11699

0 · Reply

Woodman7 Sep. 10 at 11:10 AM

$EXAS $QQQ $SPY Whoa… “Like the smartphone redefined communication, Cancerguard has the power to redefine cancer detection and the future of early intervention." Now that’s a big deal!

3 · Reply

Woodman7 Sep. 10 at 11:02 AM

$EXAS $QQQ $SPY https://finance.yahoo.com/news/exact-sciences-launches-cancerguard-first-103000596.html

1 · Reply

Woodman7 Sep. 10 at 10:37 AM

$EXAS - Baird Conference yesterday. Must watch.. https://share.google/IMlSs7SkF2Cudf9o8

0 · Reply

Market Cap	10.21B
Revenue (ttm)	2.76B
Net Income (ttm)	-1.03B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	172.31
Profit Margin	-37.29%
Debt to Equity Ratio	0.00

Volume	2,082,935
Avg Vol	3,173,478
Day's Range	N/A - N/A
Shares Out	189.32M
Stochastic %K	65%
Beta	1.05
Analysts	Strong Sell
Price Target	$65.59